Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Next Previous
Trial Profile

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Triamcinolone
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 12 May 2021 Results of a pooled analysis ( of data from a phase II NCT03011892 and two (NCT03745638 & NCT03745651) phase III studies) assessing the pharmacokinetics of Ruxolitinib published in the American Journal of Clinical Dermatology
    • 11 Feb 2020 Results assessing Effects of Ruxolitinib Cream on Pruritus and Quality of Life in Atopic Dermatitis, published in the Journal of the American Academy of Dermatology
    • 17 Oct 2019 Primary endpoint (mean percentage change from baseline in EASI score versus vehicle at Week 4) has been met as per results published at Journal of Allergy and Clinical Immunology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top